Alpha1a-adrenoceptor genetic variant triggers vascular smooth muscle cell hyperproliferation and agonist induced hypertrophy via EGFR transactivation pathway

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Gradinaru, Irina ^a   Babaeva, Ekaterina ^a   Schwinn, Debra A ^b,c   Oganesian, Anush ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BETA ARRESTIN 1; GELATINASE A; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; RETINA S ANTIGEN;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC VARIABILITY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MUSCLE CONTRACTILITY; MUSCLE HYPERTROPHY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; CELL CYCLE; DRUG EFFECTS; GENETIC VARIATION; GENETICS; HYPERTROPHY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SMOOTH MUSCLE CELL; TRANSCRIPTION INITIATION; VASCULAR SMOOTH MUSCLE;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ANIMALS; ARRESTINS; BETA-ARRESTINS; CELL CYCLE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENETIC VARIATION; HUMANS; HYPERTROPHY; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 84957110055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142787     Document Type: Article

References (91)

1. Houston MC, Dzau VJ. Hypertension as a risk factor. Vasc Med. Boston: Little Brown; 1992.
2. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension. 1993; 21: 886-893. PMID: 8505097
3. Chen L, Xin X, Eckhart AD, Yang N, Faber JE. Regulation of vascular smooth muscle growth by alpha 1-adrenoreceptor subtypes in vitro and in situ. J Biol Chem. 1995; 270: 30980-30988. PMID: 8537355
4. Xin X, Yang N, Eckhart AD, Faber JE. Alpha1D-adrenergic receptors and mitogen-activated protein kinase mediate increased protein synthesis by arterial smooth muscle. Mol Pharmacol. 1997; 51: 764-775. PMID: 9145914
5. Faber JE, Yang N, Xin X. Expression of alpha-adrenoceptor subtypes by smooth muscle cells and adventitial fibroblasts in rat aorta and in cell culture. J Pharmacol Exp Ther. 2001; 298: 441-452. PMID: 11454904
6. Teeters JC, Erami C, Zhang H, Faber JE. Systemic α1A-adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery. Am J Physiol Heart Circ Physiol. 2003; 284: H385-H392. PMID: 12388268
7. Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different α1-adrenoceptor subtypes. Circ Res. 2001; 89: 815-822. PMID: 11679412
8. Zhang H, Facemire CS, Banes AJ, Faber JE. Different α-adrenoceptors mediate migration of vascular smooth muscle cells and adventitial fibroblasts in vitro. Am J Physiol Heart Circ Physiol. 2002; 282: H2364-H2370. PMID: 12003847
9. Rokosh DG, Simpson PC. Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA. 2002; 99: 9474-9479. PMID: 12093905
10. Andersson KE, Gratzke C. Pharmacology of α1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007; 4: 368-378. PMID: 17615548
11. Tanoue A, Koshimizu TA, Shibata K, Takeo S, Tsujimoto G. Insights into α1 adrenoceptor function in health and disease from transgenic animal studies. Trends Endocrinol Metab. 2003; 14: 107-113. PMID: 12670735
12. Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T, et al. The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest. 2002; 109: 765-775. PMID: 11901185
13. Hosoda C, Koshimizu TA, Tanoue A, Nasa Y, Oikawa R, Tomabechi T, et al. Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol. 2005; 67: 912-922. PMID: 15598970
14. Chen Z, Minneman KP. Recent progress in α1-adrenergic receptor research. Acta Pharmacologica Sinica. 2005; 26: 1281-1287. PMID: 16225747
15. Piascik MT, Hrometz SL, Edelmann SE, Guarino RD, Hadley RW, Brown RD. Immunocytochemical localization of the α1Badrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: analysis with selective ligands and antisense oligonucleotides. J Pharmacol Exp Ther. 1997; 283: 854-868. PMID: 9353407
16. Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation. 1999; 100: 2336-2343. PMID: 10587338
17. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol. 2007; 213: 589-602. PMID: 17786953
18. Touyz RM. Recent advances in intracellular signaling in hypertension. Curr Opin Nephrol Hypertens. 2003; 12: 165-174. PMID: 12589177
19. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002; 8: 35-40. PMID: 11786904
20. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci. 2001; 947: 42-55. PMID: 11795306
21. Nagareddy PR, MacLeod KM, McNeill JH. GPCR agonist-induced transactivation of the EGFR upregulates MLC II expression and promotes hypertension in insulin-resistant rats. Cardiovasc Res. 2010; 87: 177-186. doi: 10.1093/cvr/cvq030 PMID: 20110336
22. Nagareddy PR, Chow FL, Hao L, Wang X, Nishimura T, MacLeod KM, et al. Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochondrial ATP synthesis. Cardiovasc Res. 2009; 84: 368-377. doi: 10.1093/cvr/cvp230 PMID: 19578070
23. Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res. 2004; 95: 989-997. PMID: 15486316
24. Ulu N, Gurdal H, Landheer SW, Duin M, Guc MO, Buikema H, et al. α1-Adrenoceptor-mediated contraction of rat aorta is partly mediated via transactivation of the epidermal growth factor receptor. Br J Pharmacol. 2010; 161: 1301-1310. doi: 10.1111/j.1476-5381.2010.00829.x PMID: 20977469
25. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res. 2004; 94: 68-76. PMID: 14656925
26. Shah BH, Shah FB, Catt KJ. Role of metalloproteinase-dependent EGF receptor activation in alphaadrenoceptor-stimulated MAP kinase phosphorylation in GT1-7 neurons. J Neurochem. 2006: 96: 520-532. PMID: 16336626
27. Kreda SM, Sumner M, Fillo S, Ribeiro CM, Luo GX, Xie W, et al. Alpha(1)-adrenergic receptors mediate LH-releasing hormone secretion through phospholipases C and A(2) in immortalized hypothalamic neurons. Endocrinology. 2001; 142: 4839-4851. PMID: 11606452
28. Faber JE, Szymeczek CL, Salvi SS, Zhang H. Enhanced alpha1-adrenergic trophic activity in pulmonary artery of hypoxic pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol. 2006; 291: H2272-2281. PMID: 16798826
29. Oganesian A, Yarov-Yarovoy V, Parks WC, Schwinn DA. Constitutive coupling of a naturally occurring human alpha1a-adrenergic receptor genetic variant to EGFR transactivation pathway. Proc Natl Acad Sci U S A. 2011; 108: 19796-19801. doi: 10.1073/pnas.1116271108 PMID: 22089237
30. Lei B, Schwinn DA, Morris DP. Stimulation of α1a Adrenergic Receptors Induces Cellular Proliferation or Antiproliferative Hypertrophy Dependent Solely on Agonist Concentration. PloSOne. 2013; 8: e72430.
31. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. β-arrestins and cell signaling. Annu Rev Physiol. 2007; 69: 483-510. PMID: 17305471
32. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, et al. β-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007; 117: 2445-2458. PMID: 17786238
33. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK. Sequential binding of agonists to the β2 adrenoceptor: kinetic evidence for intermediate conformational states. J Biol Chem. 2004; 279: 686-691. PMID: 14559905
34. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA. 2003; 100: 10782-10782. PMID: 12949261
35. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov. 2010; 9: 373-386. doi: 10.1038/nrd3024 PMID: 20431569
36. Reder NP, Tayo BO, Salako B, Ogunniyi A, Adeyemo A, Rotimi C, et al. Adrenergic alpha-1 pathway is associated with hypertension among Nigerians in a pathway-focused analysis. PLoSOne. 2012; 7: e37145.
37. Masuo K. Adrenoceptor polymorphisms in hypertension and diabetes with obesity-update in 2014. Curr Hypertens Rev. 2014; Aug 12, (Epub ahead of print).
38. Femminella GD, Barrese V, Ferrara N, Rengo G. Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. Pharmgenomics Pers Med. 2014; 7: 267-273. doi: 10.2147/PGPM.S49799 PMID: 25276090
39. Hernαndez-Pacheco G, Gonzαlez-Hermosillo A, Murata C, Yescas P, Esp?nola-Zavaleta N, Mart?nez M, et al. Arg347Cys polymorphism of α 1a-adrenergic receptor in vasovagal syncope. Case-control study in a Mexican population. Auton Neurosci. 2004; 183: 66-71.
40. Lei B, Morris DP, Smith MP, Svetkey LP, Newman MF, Rotter JI, et al. Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn Schmiedebergs Arch Pharmacol. 2005; 371: 229-239. PMID: 15900517
41. Kleine-Brueggeney M, Gradinaru I, Babaeva E, Schwinn DA, Oganesian A. Alpha1a-adrenoceptor genetic variant induces cardiomyoblast-to-fibroblast-like cell transition via distinct signaling pathways. Cell Signal. 2014; 26: 1985-1997. doi: 10.1016/j.cellsig.2014.05.007 PMID: 24835978
42. Hori Y, Kashimoto T, Yonezawa T, Sano N, Saitoh R, Igarashi S, et al. Matrix Metalloproteinase-2 stimulates collagen-I expression through phosphorylation of focal adhesion kinase in rat cardiac fibroblasts. Am J Physiol Cell Physiol. 2012; 303: C947-C953. doi: 10.1152/ajpcell.00401.2011 PMID: 22914642
43. Delgado-Olguin P, Huang Y, Li X, Christodoulou D, Seidma CE, Seidman JG, et al. Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet. 2012; 44: 343-347. doi: 10.1038/ng.1068 PMID: 22267199
44. Poppleton HM, Wiepz GJ, Bertics PJ, Patel TB. Modulation of the protein tyrosine kinase activity and autophosphorylation of the epidermal growth factor receptor by its juxtamembrane region. Arch Biochem Biophys. 1999; 363: 227-236. PMID: 10068444
45. Kim J, Ahn S, Rajagopal K, Lefkowitz RJ. Independent β-Arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem. 2009; 284: 11953-11962. doi: 10.1074/jbc.M808176200 PMID: 19254952
46. Kendall RT, Lee MH, Pleasant DL, Robinson K, Kuppuswamy D,McDermott PJ, et al. Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis. J Biol Chem. 2014; 289: 26155-26166. doi: 10.1074/jbc.M114.595728 PMID: 25081544
47. Smiljanic K, Obradovic M, Jovanovic A, Djordjevic J, Dobutovic B, Jevremovic D, et al. Thrombin stimulates VSMC proliferation through an EGFR-dependent pathway: involvement of MMP-2. Mol Cell Biochem. 2014; 396: 147-160. doi: 10.1007/s11010-014-2151-y PMID: 25047892
48. Bakken AM, Protack CD, Roztocil E, Nicholl SM, Davies MG. Cell migration in response to the aminoterminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAMmediated mechanism. J Vasc Surg. 2009; 49: 1296-1303. doi: 10.1016/j.jvs.2008.12.026 PMID: 19394555
49. Kim I, Tilley DG, Chen J, Salazar NC,Whalen EJ, Violin JD, et al. β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Nat. Acad Sci USA. 2008; 105: 14555-14560. doi: 10.1073/pnas.0804745105 PMID: 18787115
50. Chiu CL, Digman MA, Gratton E. Cell matrix remodeling ability shown by image spatial correlation. J Biophys. 2013;Id532030.
51. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens. 2005; 14: 125-131. PMID: 15687838
52. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med. 2011; 13: e11. doi: 10.1017/S1462399411001815 PMID: 21450123
53. Patel PA, Tilley DG, Rockman HA. Physiologic and cardiac roles of β-arrestins. J Mol Cell Cardiol. 2009; 46: 300-308. doi: 10.1016/j.yjmcc.2008.11.015 PMID: 19103204
54. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al. β-Arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J Biol Chem. 2006; 281: 1261-1273. PMID: 16280323
55. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, et al. Distinct β-arrestin-and G proteindependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 2006; 281: 10856-10864. PMID: 16492667
56. Ahn S, Wei H, Garrison TR, Lefkowitz RJ. Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by β-arrestins 1 and 2. J Biol Chem. 2004; 279: 7807-7811. PMID: 14711824
57. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by Gprotein-coupled receptors. Nature. 1996; 379: 557-560. PMID: 8596637
58. Pierce KL, Luttrell LM, Lefkowiz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene. 2001; 20: 1532-1539. PMID: 11313899
59. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogenactivated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998; 273: 8890-8896. PMID: 9535870
60. Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, et al. Src and Pyk2 mediate Gprotein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. J Biol Chem. 2001; 276: 20130-20135. PMID: 11274221
61. Block ER, Tolino MA, Klarlund JK. Pyk2 activation triggers epidermal growth factor receptor signaling and cell motility after wounding sheets of epithelial cells. J Biol Chem. 2010; 285: 13372-13379. doi: 10.1074/jbc.M109.083089 PMID: 20215112
62. Sato K, Sato A, Aoto M, Fukami Y. c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem Biophys Res Commun. 1995; 215: 1078-1087. PMID: 7488034
63. Belsches AP, Haskell MD, Parsons SJ. Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front Biosci. 1997; 2: d501-d518. PMID: 9331427
64. Sato KI. Cellular functions regulated by phosphorylation of EGFR on Tyr845. Int J Mol Sci. 2013; 14: 10761-10790. doi: 10.3390/ijms140610761 PMID: 23702846
65. Drube S, Stirnweiss J, Valkova C, Liebmann C. Ligand-independent and EGF receptor-supported transactivation: Lessons from β2-adrenergic receptor signalling. Cell Signal. 2006; 18: 1633-1646. PMID: 16495036
66. Du T, Li B, Liu S, Zang P, Prevot V, Hertz L, et al. ERK phosphorylation in intact, adult brain by α2-adrenergic transactivation of EGF receptors. Neurochem Int. 2009; 55: 593-600. PMID: 19501623
67. Liu A, Garg P, Yang S, Gong P, Pallero MA, Annis DS, et al. Epidermal growth factor-like repeats of thrombospondins activate phospholipase C? and increase epithelial cell migration through indirect epidermal growth factor receptor activation. J Biol Chem. 2009; 284: 6389-6402. doi: 10.1074/jbc. M809198200 PMID: 19129184
68. Liu YT, Song L, Templeton DM. Heparin suppresses lipid raft-mediated signaling and ligand-independent EGF receptor activation. J Cell Physiol. 2007; 211: 205-212. PMID: 17226785
69. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, et al. Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation. 2009; 119: 2480-2489. doi: 10.1161/CIRCULATIONAHA. 108.835488 PMID: 19398663
70. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006; 69: 614-624. PMID: 16266693
71. Lee SJ, Seo KW, Yun MR, Bae SS, Lee WS, Hong KW, et al. 4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NFkappaB signaling pathways. Free Radic Biol Med. 2008; 45: 1487-1492. PMID: 18805481
72. Risinger GM Jr, Hunt TS, Updike DL, Bullen EC, Howard EW. Matrix metalloproteinase-2 expression by vascular smooth muscle cells is mediated by both stimulatory and inhibitory signals in response to growth factors. J Biol Chem. 2006; 281: 25915-25925. PMID: 16854986
73. Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH, et al. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol. 2007; 292: H2438-H2448. PMID: 17237246
74. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, et al. Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium. 2006; 13: 227-231. PMID: 16840178
75. Lemarié CA, Tharaux PL, Lehoux S. Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol. 2010; 48: 433-439. doi: 10.1016/j.yjmcc.2009.09.018 PMID: 19837080
76. Kim YH, Lee SJ, Seo KW, Bae JU, Park SY, Kim EK, et al. PAF enhances MMP-2 production in rat aortic VSMCs via a β-arrestin2-dependent ERK signaling pathway. J Lipid Res. 2013; 54: 2678-2686. doi: 10.1194/jlr.M037176 PMID: 23911909
77. Shah BH, Yesilkaya A, Olivares-Reyes JA, Chen HD, Hunyady L, Catt KJ. Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor. Mol Endocrinol. 2004; 18: 2035-2048. PMID: 15143154
78. Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, et al. Intracellular Signaling of Angiotensin II-induced p70 S6 Kinase Phosphorylation at Ser 411 in Vascular Smooth Muscle Cells. Possible requirement of Epidermal Growth Factor Receptor, Ras, Extracellular Signal-Regulated Kinase, and Akt. J Biol Chem. 1999; 274: 36843-36851. PMID: 10601235
79. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012; 40: 139-146. doi: 10.1042/BST20110609 PMID: 22260680
80. Kiyatkin A, Aksamitiene E, Markevich NI, Borisov NM, Hoek JB, Kholodenko BN. Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. J Biol Chem. 2006; 28: 19925-19938.
81. Hayashi H, Tsuchiya Y, Nakayama K, Satoh T, Nishida E. Down-regulation of the PI3-kinase/Akt pathway by ERK MAP kinase in growth factor signaling. Genes Cells. 2008; 13: 941-947. doi: 10.1111/j. 1365-2443.2008.01218.x PMID: 18691227
82. Choi WS, Sung CK. Inhibition of phosphatidylinositol-3-kinase enhances insulin stimulation of insulin receptor substrate 1 tyrosine phosphorylation and extracellular signal-regulated kinases in mouse Rfibroblasts. J Recept Signal Transduction Res. 2004; 24: 67-83.
83. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011; 30: 2547-2557. doi: 10.1038/onc.2010.626 PMID: 21278786
84. Borisov N, Aksamitiene E, Kiyatkin A, Legewie S, Berkhout J, Maiwald T, et al. Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol Syst Biol. 2009; 5: 256. doi: 10. 1038/msb.2009.19 PMID: 19357636
85. Guo J, Gertsberg Z, Ozgen N, Steinberg SF. p66Shc Links 1-Adrenergic Receptors to a Reactive Oxygen Species-Dependent AKT-FOXO3A Phosphorylation Pathway in Cardiomyocytes. Circ Res. 2009; 104: 660-669. doi: 10.1161/CIRCRESAHA.108.186288 PMID: 19168439
86. Barki-Harrington L, Perrino C, Rockman HA. Network integration of the adrenergic system in cardiac hypertrophy. Cardiovasc Res. 2004; 63: 391-402. PMID: 15276464
87. Li Y, Zhang H, Liao W, Song Y, Ma X, Chen C, et al. Transactivated EGFR mediates α1-AR-induced STAT3 activation and cardiac hypertrophy. Am J Physiol-Heart C. 2011; 301: H1941-H1951.
88. Rao RS, Miano JM, Olson EN, Seidel CL. The A10 cell line: a model for neonatal, neointimal, or differentiated vascular smooth muscle cells. Cardiovasc Res. 1997; 36: 118-126. PMID: 9415280
89. Kennedy E, Hakimjavadi R, Greene C, Mooney CJ, Fitzpatrick E, Collins LE, et al. Embryonic rat vascular smooth muscle cells revisited-a model for neonatal, neointimal SMC or differentiated vascular stem cells. Vasc Cell. 2014; 6: 6. doi: 10.1186/2045-824X-6-6 PMID: 24628920
90. Oishi K, Ogawa Y, Gamoh S, Uchida MK. Contractile responses of smooth muscle cells differentiated from rat neural stem cells. Journal of Physiology. 2002: 540: 139-152. PMID: 11927676
91. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90: 251-262. PMID: 11861412